Wholesalers Say Novo Can't Duck GLP-1 Antitrust Suits
By Bryan Koenig · June 24, 2026, 7:04 PM EDT
Drug buyers want a New York federal judge to preserve proposed class claims accusing Novo Nordisk of paying Teva to delay generic competition with its Victoza GLP-1 drug, arguing that whatever...
To view the full article, register now.